Phase I to study pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the reference biologic, Neulasta
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 05 Aug 2018 Results published in the British Journal of Clinical Pharmacology.
- 12 Dec 2017 New trial record
- 09 Dec 2017 Primary endpoint (Determine PK similarity) has been met, according to results presented at the 40th Annual San Antonio Breast Cancer Symposium.